TG THERAPEUTICS, INC. Earnings Per Share (Diluted)
TG THERAPEUTICS, INC. (TGTX) reported Earnings Per Share (Diluted) of $0.05 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-05
- TG THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2026-06-30 was $0.05, a 70.59% decline year-over-year.
- TG THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2026-03-31 was $0.12, a 300.00% increase year-over-year.
- TG THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-12-31 was $0.14, a 0.68% decline year-over-year.
- TG THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-09-30 was $2.43, a 12050.00% increase year-over-year.
- TG THERAPEUTICS, INC. earnings per share, diluted for fiscal 2025 was $2.77, a 1746.67% increase from fiscal 2024.
- TG THERAPEUTICS, INC. earnings per share, diluted for fiscal 2024 was $0.15, a 66.67% increase from fiscal 2023.
- TG THERAPEUTICS, INC. earnings per share, diluted for fiscal 2023 was $0.09.
- TG THERAPEUTICS, INC. earnings per share, diluted for fiscal 2022 was -$1.65.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.05 10-Q · filed 2026-08-05 | $0.17 10-Q · filed 2026-08-05 | $0.32 derived: net income ÷ weighted average shares · filed 2026-08-05 | $2.77 derived: net income ÷ weighted average shares · filed 2026-08-05 | |
| 2026-03-31 | $0.12 10-Q · filed 2026-05-06 | $0.27 derived: net income ÷ weighted average shares · filed 2026-08-05 | $2.71 derived: net income ÷ weighted average shares · filed 2026-08-05 | $2.87 derived: net income ÷ weighted average shares · filed 2026-08-05 | |
| 2025-12-31 | $0.14 derived: net income ÷ weighted average shares · filed 2026-04-30 | $2.58 derived: net income ÷ weighted average shares · filed 2026-04-30 | $2.75 derived: net income ÷ weighted average shares · filed 2026-08-05 | $2.77 10-K · filed 2026-02-27 | |
| 2025-09-30 | $2.43 10-Q · filed 2025-11-05 | $2.59 derived: net income ÷ weighted average shares · filed 2026-08-05 | $2.62 10-Q · filed 2025-11-05 | $2.77 derived: net income ÷ weighted average shares · filed 2026-08-05 | |
| 2025-06-30 | $0.17 10-Q · filed 2026-08-05 | $0.20 10-Q · filed 2026-08-05 | $0.35 derived: net income ÷ weighted average shares · filed 2026-08-05 | $0.37 derived: net income ÷ weighted average shares · filed 2026-08-05 | |
| 2025-03-31 | $0.03 10-Q · filed 2026-05-06 | $0.18 derived: net income ÷ weighted average shares · filed 2026-08-05 | $0.20 derived: net income ÷ weighted average shares · filed 2026-08-05 | $0.24 derived: net income ÷ weighted average shares · filed 2026-08-05 | |
| 2024-12-31 | $0.15 derived: net income ÷ weighted average shares · filed 2026-04-30 | $0.17 derived: net income ÷ weighted average shares · filed 2026-04-30 | $0.21 derived: net income ÷ weighted average shares · filed 2026-04-30 | $0.15 10-K · filed 2026-02-27 | |
| 2024-09-30 | $0.02 10-Q · filed 2025-11-05 | $0.07 derived: net income ÷ weighted average shares · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | -$0.09 derived: net income ÷ weighted average shares · filed 2026-04-30 | |
| 2024-06-30 | $0.04 10-Q · filed 2025-08-08 | -$0.03 10-Q · filed 2025-08-08 | -$0.12 derived: net income ÷ weighted average shares · filed 2026-04-30 | $0.62 derived: net income ÷ weighted average shares · filed 2026-04-30 | |
| 2024-03-31 | -$0.07 10-Q · filed 2025-05-09 | -$0.17 derived: net income ÷ weighted average shares · filed 2026-04-30 | $0.58 derived: net income ÷ weighted average shares · filed 2026-04-30 | $0.27 derived: net income ÷ weighted average shares · filed 2026-04-30 | |
| 2023-12-31 | -$0.09 derived: net income ÷ weighted average shares · filed 2026-04-30 | $0.64 derived: net income ÷ weighted average shares · filed 2026-04-30 | $0.34 derived: net income ÷ weighted average shares · filed 2026-04-30 | $0.09 10-K · filed 2026-02-27 | |
| 2023-09-30 | $0.73 10-Q · filed 2024-11-07 | $0.45 derived: net income ÷ weighted average shares · filed 2024-11-07 | $0.19 10-Q · filed 2024-11-07 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-04-30 | |
| 2023-06-30 | -$0.34 10-Q · filed 2024-08-09 | -$0.62 10-Q · filed 2024-08-09 | -$1.00 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.27 derived: net income ÷ weighted average shares · filed 2026-04-30 | |
| 2023-03-31 | -$0.28 10-Q · filed 2023-05-08 | -$0.66 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.93 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.23 derived: net income ÷ weighted average shares · filed 2026-04-30 | |
| 2022-12-31 | -$0.39 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.65 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.95 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.65 10-K · filed 2025-03-03 | -$1.46 10-K · filed 2023-03-01 |
| 2022-09-30 | -$0.26 10-Q · filed 2023-11-06 | -$0.57 derived: net income ÷ weighted average shares · filed 2023-11-06 | -$1.08 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | -$0.30 10-Q · filed 2023-08-04 | -$0.81 10-Q · filed 2023-08-04 | |||
| 2022-03-31 | -$0.51 10-Q · filed 2023-05-08 | ||||
| 2021-12-31 | -$2.63 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | -$0.65 10-Q · filed 2022-11-09 | -$1.93 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | -$0.59 10-Q · filed 2022-08-09 | -$1.28 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | -$0.69 10-Q · filed 2022-05-10 | ||||
| 2020-12-31 | -$2.42 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |